BIDMC Researchers ID and Treat Faulty Brain Circuitry That Causes Disabling Symptoms of Schizophrenia
Jacqueline Mitchell (BIDMC Communications) 617-667-7306, firstname.lastname@example.org
JANUARY 30, 2019
Study: Non-invasive brain stimulation alleviates the chronic, treatment-resistant symptoms of schizophrenia
BOSTON – Schizophrenia is a chronic and disabling mental illness that affects more than three million Americans. Anti-psychotic medication can control schizophrenia’s psychotic symptoms, including the hallucinations and delusions that are well-known hallmarks of the disease. However, there are no effective treatments for the disease’s ‘negative symptoms’ – so-called because they involve a loss of normal function. The negative symptoms of schizophrenia include an inability to feel pleasure, a lack of motivation and difficulty with non-verbal communication. These symptoms can seriously impact patients’ employment prospects, housing, relationships and overall quality of life.
In a first-of-its-kind study, researchers at Beth Israel Deaconess Medical Center (BIDMC) used imaging data to determine the underlying anatomical cause of schizophrenia’s negative symptoms and then applied non-invasive brain stimulation to ameliorate them. The scientists found, as they reported today in the American Journal of Psychiatry, that these symptoms arise from a breakdown in a network between the brain’s prefrontal cortex and the cerebellum. Moreover, the team demonstrated that a novel type of non-invasive brain stimulation restored this crucial network’s function, which in turn improved schizophrenia’s most debilitating and treatment resistant symptoms in patients with the disease.
In stage one of this two-pronged study, Brady and colleagues examined functional magnetic resonance imaging (fMRI) scans of 44 patients with schizophrenia. Their analysis revealed that a breakdown in the neural connectivity between the prefrontal cortex and cerebellum was linked to more severe negative symptoms. (The network in question was not associated with hallucinations or delusions.)
“We wanted to find out if we could restore that brain circuit through non-invasive brain stimulation, and if we could, would people get better?” said corresponding author Mark Halko, PhD, assistant professor of neurology at BIDMC’s Berenson-Allen Center for Non-Invasive Brain Stimulation. “The answer is they absolutely do get better. It’s a very provocative finding.”
Halko, an expert in non-invasive brain stimulation, focuses on using the technology – which modifies brain activity using powerful magnetic fields – to relieve symptoms of anxiety, depression and other mental illnesses. In 2012, Halko was principal investigator on a clinical trial testing whether non-invasive brain stimulation could improve symptoms in patients with schizophrenia. But without a known circuit to explain treatment response, the study raised more questions than it answered. Then a mutual colleague introduced Brady and Halko.
“When we started looking at our data sets together, we came to the conclusion that if Dr. Brady’s work could identify the networks that are responsible for these symptoms of the illness, then the brain modulation we’ve been doing could change that exact network,” Halko said.
To test that idea, the researchers recruited patients diagnosed with schizophrenia, quantified and scored their negative symptom severity and conducted baseline brain imaging. Next, Halko and colleagues administered either active non-invasive brain stimulation or a sham (placebo) treatment as a control. Participants received two brain stimulation sessions per day, four hours apart, for five consecutive days.
Follow-up brain scans and clinical evaluation revealed that patients with schizophrenia who experienced increased connectivity between the brain’s prefrontal cortex and cerebellum after brain stimulation also experienced a reduction in symptom severity.
“For some people with schizophrenia, the non-invasive brain stimulation had a powerful impact; for others, it wasn’t as powerful,” said Brady. “In all cases, re-connecting the network explained how much improvement the patient experienced. For the first time, we know what brain circuit to go after.”
In addition to Brady and Halko, co-investigators included Ivy Lee, Larry J. Seidman, PhD, Matcheri S. Keshavan, MD, and Alvaro Pascual-Leone, MD, PhD, of Beth Israel Deaconess Medical Center; Dost Öngür, MD, PhD, of McLean Hospital; Irene Gonsalvez, MD, of St. Elizabeth’s Medical Center; Jeremy D. Schmahmann, MD, of Massachusetts General Hospital; Shaun M. Eack, PhD, of University of Pittsburgh.
This work was supported in part by awards from the National Institutes of Health, including the National Institute of Mental Health, the National Center for Research Resources, and the National Center for the Advancement of Translational Science (NIMH K23 MH100623; R01 MH111868; R01 MH092440; K24 MH104449; UL1 RR025758). Additional partial support was provided by Sidney R. Baer Jr. Foundation; MINDlink Foundation; Harvard Catalyst; and The Harvard Clinical and Translational Science Center.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox.
Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,800 physicians and 36,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.